ANAPTYSBIO, INC. Deferred Tax Assets, Deferred Income
ANAPTYSBIO, INC. (ANAB) had Deferred Tax Assets, Deferred Income of $6.36 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2025-02-27
- 2024-12-31: Deferred Tax Assets, Deferred Income $6.36M.
- 2023-12-31: Deferred Tax Assets, Deferred Income $6.98M.
- 2022-12-31: Deferred Tax Assets, Deferred Income $7.37M.
- 2021-12-31: Deferred Tax Assets, Deferred Income $0.00.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2024-12-31 | $6.36M 10-K · filed 2025-02-27 |
| 2023-12-31 | $6.98M 10-K · filed 2025-02-27 |
| 2022-12-31 | $7.37M 10-K · filed 2024-03-11 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |